A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study.
OBJECTIVE
To determine if changes in B-type natriuretic peptide (BNP) levels can accurately reflect acute changes in pulmonary capillary wedge pressure during treatment of decompensated heart failure.


BACKGROUND
Tailored therapy of decompensated congestive heart failure with hemodynamic monitoring is controversial. Other than the expense and complications of Swan-Ganz catheters, its use in titration of drug therapy has no conclusive end point. Because BNP reflects both elevated left ventricular pressure and neurohormonal modulation and has a short half-life, we hypothesized that levels of BNP would decline in association with falling wedge pressures. Final BNP levels would perhaps signify a new set point of neuromodulation.


RESULTS
Twenty patients with decompensated New York Heart Association (NYHA) class III-IV congestive heart failure (CHF) undergoing tailored therapy were studied. BNP levels were drawn every 2 to 4 hours for the first 24 hours (active treatment phase) and then every 4 hours for the next 24 to 48 hours (stabilization period). Hemodynamic data was recorded simultaneously. In 15 patients whose wedge pressure responded to treatment in the first 24 hours, there was a significant drop in BNP levels (55%) versus nonresponders (8%). There was a significant correlation between percent change in wedge pressure from baseline per hour and the percent change of BNP from baseline per hour (r = 0.79, P <.05). When the wedge pressure was kept at a stable, low level during the stabilization phase, BNP levels continued to fall another 37% (937 +/- 140 pg/mL at 24 hours to 605 +/- 128 pg/mL). Patients who died (n = 4) had higher final BNP levels (1,078 +/- 123 pg/mL v 701 +/- 107 pg/mL).


CONCLUSIONS
The data suggest that rapid testing of BNP may be an effective way to improve the in-hospital management of patients admitted with decompensated CHF. Although BNP levels will not obviate the need for invasive hemodynamic monitoring, it may be a useful adjunct in tailoring therapy to these patients.
Kazanegra
R
R
Division of Cardiology, Department of Medicine, Veteran's Affairs Medical Center, San Diego, California 92161, USA.
Cheng
V
V
Garcia
A
A
Krishnaswamy
P
P
Gardetto
N
N
Clopton
P
P
Maisel
A
A
D000368:Aged; D009320:Atrial Natriuretic Factor / Q000097:blood* / Q000494:pharmacology; D001806:Blood Urea Nitrogen; D006333:Heart Failure / Q000097:blood / Q000401:mortality / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain; D010865:Pilot Projects; D011379:Prognosis; D011669:Pulmonary Wedge Pressure / Q000187:drug effects / Q000502:physiology*; D016019:Survival Analysis; D013997:Time Factors
D020097:Natriuretic Peptide, Brain; D009320:Atrial Natriuretic Factor